SANOFI 75.810 € (+0,74 %)
GETLINK SE 18.730 € (+1,19 %)
AKZO NOBEL 60.800 € (+1,00 %)
ASR NEDERLAND 66.560 € (-0,03 %)
CAPGEMINI 91.900 € (+0,37 %)
SHELL PLC 33.885 € (-0,24 %)
GENFIT 12.940 € (+22,31 %)
TECHNIP ENERGIES 34.520 € (+3,42 %)
ASM INTERNATIONAL 975.600 € (+4,10 %)
AIR LIQUIDE 180.300 € (+0,16 %)
AHOLD DEL 35.920 € (-0,66 %)
AB SCIENCE 0.773 € (+0,78 %)
ING GROEP N.V. 28.290 € (+0,21 %)
ALLFUNDS GROUP 8.575 € (+0,53 %)
MICHELIN 34.840 € (+0,35 %)
CROSSJECT 1.800 € (+0,67 %)
SBM OFFSHORE 30.680 € (+2,40 %)
DSM FIRMENICH AG 85.000 € (+2,29 %)
ACCOR 50.900 € (+0,35 %)
VALEO 13.275 € (+2,55 %)
VOLTALIA 7.200 € (+1,27 %)
AIR FRANCE -KLM 13.395 € (-0,37 %)
EUROPACORP 0.266 € (+9,92 %)
PHILIPS KON 24.690 € (+1,94 %)
ENGIE 27.730 € (+2,06 %)
LEGRAND 143.350 € (+1,59 %)
DNXCORP 17.750 € (-0,56 %)
UMG 18.995 € (-0,73 %)
ICADE 19.230 € (-0,83 %)
JCDECAUX 20.100 € (+1,11 %)
IPSEN 170.700 € (-0,23 %)
EUROCOMMERCIAL 27.450 € (0,00 %)
GECINA 72.800 € (-0,21 %)
UNILEVER 54.080 € (-0,39 %)
ADYEN 862.300 € (+0,85 %)
TKH GROUP 43.820 € (+2,19 %)
ABC ARBITRAGE 5.260 € (+0,57 %)
L'OREAL 382.450 € (-1,42 %)
STELLANTIS NV 4.930 € (-3,47 %)
AMG 33.080 € (+2,61 %)
SPIE 52.750 € (+5,50 %)
HERMES INTL 1 641.000 € (-0,36 %)
FUGRO 9.475 € (+0,74 %)
EXAIL TECHNOLOGIES 122.500 € (+0,99 %)
ARCADIS 33.780 € (+2,80 %)
S.E.B. 48.780 € (+0,58 %)
DASSAULT SYSTEMES 18.495 € (-0,94 %)
ORANGE 15.860 € (-0,06 %)
RENAULT 26.370 € (+1,66 %)
WOLTERS KLUWER 57.620 € (+0,07 %)
FRANCAISE ENERGIE 42.100 € (+5,25 %)
AIRBUS 206.150 € (+1,10 %)
VALNEVA 2.337 € (+4,10 %)
APERAM 45.500 € (+3,60 %)
THALES 238.200 € (-0,92 %)
ARCELORMITTAL SA 58.600 € (+5,89 %)
AEGON 7.672 € (+0,87 %)
NN GROUP 75.940 € (-0,24 %)
DRONE VOLT 0.389 € (+2,42 %)
BOLLORE 4.144 € (+0,83 %) |
28/03/2023 16:00
Veriheal Releases Latest Medical Cannabis Report Detailing Generational Product PreferencesNational Survey Data Provide Insights for Improving the Industry to Better Meet Patients' Diverse Needs DENVER, CO / ACCESSWIRE / March 28, 2023 / Veriheal today revealed findings from its annual Medical Cannabis Preference Report, a yearly analysis that explores the health goals and preferences of U.S. medical cannabis patients using segmented survey data. The 2022 report analyzed the relationship between generations and cannabis consumption methods to better understand varying health objectives across age groups. Veriheal collaborated with members of NORML, the University of Maryland School of Pharmacy, and the University of California, Los Angeles to compile the report, which gathered information from 200,000 anonymized adult patients who signed up for an appointment with a medical cannabis doctor using Veriheal's platform in 2022. Upon registering with Veriheal, patients answered assorted questions regarding their medical needs and cannabis use. Findings show that baby boomers and Generation X mostly prefer edibles (63%), followed closely by cannabis flower (61%). Contrarily, millennials and Generation Z demonstrated a strong preference for flower (79%) as well as more interest in concentrates than the older generations. Older patients primarily reported using cannabis for chronic pain (58%), while the most common condition reported by younger patients was trouble sleeping (64%). "Veriheal is committed to helping the medical cannabis industry better serve all patients with the aid of data-driven intelligence," said Anthony Dutcher, Veriheal CMO. The study also assessed whether state cannabis legalization status plays a role in patient product preferences. While no major differences were spotted between states with differing cannabis laws, additional research points to product availability and advertising practices as factors in patient preferences. For a deep dive into the findings, view the full report here. About Veriheal Veriheal is a healthcare technology company that is the largest facilitator of medical marijuana cards in the nation. Its mission is to educate and advocate on behalf of patients and secure their safe access to regulated medical cannabis products. The company has a culture of open communication and transparency with its clients and operates as a concierge service to ensure HIPAA-compliant connections between patients and physicians via its proprietary platform. Visit veriheal.com for more information. Media Contact Information: Anthony Dutcher SOURCE: Veriheal View source version on accesswire.com: https://www.accesswire.com/745994/Veriheal-Releases-Latest-Medical-Cannabis-Report-Detailing-Generational-Product-Preferences Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière